Quantcast

Latest Methotrexate Stories

2009-05-13 21:48:00

- Available this week, Cimzia(R) (certolizumab pegol), the only pegylated anti-TNF, offers a new treatment option for U.S. adult patients suffering from moderately to severely active rheumatoid arthritis - Patients treated with Cimzia(R), together with methotrexate, experienced rapid and significant improvements in signs and symptoms, physical function and pain as early as week one, and sustained at week 24 and for up to one year - Patients treated with Cimzia(R) as a monotherapy...

2009-04-27 08:31:40

The U.S. Food and Drug Administration says it has approved Simponi, a monthly injectable treatment for three types of arthritis. The FDA said Simponi (golimumab) was approved for use by adults with moderate-to-severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis. All three conditions are chronic disorders in which the immune system attacks multiple joints, causing stiffness, pain and restricted motion. Today's approval provides another treatment option for...

2009-04-13 15:15:00

Canadian Approval Is World's First Regulatory Approval for SIMPONI HORSHAM, Pa. and KENILWORTH, N.J., April 13 /PRNewswire-FirstCall/ Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that Health Canada has granted approval of SIMPONI (TM) (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS)....

2009-04-09 03:43:00

JAKARTA, Indonesia, April 9 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints. The most visible symptoms of RA are swollen joints and crippling stiffness, particularly of the hands and feet. It can cause fatigue, fever, loss of appetite and also impedes mobility and quality of life. (Logo:...

2009-01-28 08:50:00

Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemiaScientists from St. Jude Children's Research Hospital and the Children's Oncology Group (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic variations that clinicians might be able to use as guideposts for designing more effective chemotherapy for this...

2009-01-27 15:00:00

Scan of thousands of inherited genetic changes reveal specific variations linked to treatment failure and the fate of chemotherapy drugs in the body for children with acute lymphoblastic leukemia MEMPHIS, Tenn., Jan. 27 /PRNewswire-USNewswire/ -- Scientists from St. Jude Children's Research Hospital and the Children's Oncology Group (COG) have discovered in children with acute lymphoblastic leukemia (ALL) scores of inherited genetic variations that clinicians might be able to use as...

2009-01-14 09:12:50

Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. It enters the cell via several pathways, one of which involves folate receptor ÃŽ² (FRÃŽ²), which is highly specific for cells present in the joints of patients with rheumatoid arthritis (RA). During the last two decades, a second generation of folate antagonists has been designed to address...

2009-01-08 12:15:00

The life of a Minnesota boy suffering with a rare and serious form of the genetic disorder Pompe disease has been extended after treatment with a drug typically used to suppress the immune system of those with cancer and rheumatoid arthritis.Rituxan, or rituximab,  is a monoclonal antibody made by Genentech Inc and Biogen Idec.  It consists of genetically engineered immune system molecules, and is used to treat non-Hodgkin's lymphoma, rheumatoid arthritis and other conditions.Dr....

2008-12-04 00:30:00

NUTLEY, N.J., Dec. 4 /PRNewswire/ -- Roche today announced that the U.S. Food and Drug Administration (FDA) has provided further guidance on the requirements for the Biologics License Application (BLA) for ACTEMRA(R) (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). As a result of the FDA's evolving Risk Evaluation and Mitigation Strategy (REMS)...

2008-11-13 09:00:37

CHARLOTTE, N.C., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has begun dosing volunteers in the single ascending dose (SAD) study of its Phase I clinical program for CH-4051, the second drug candidate from its portfolio of orally available, non-metabolized antifolates engineered to provide potent anti-inflammatory activity without the liver and kidney toxicities or tolerability related side effects associated with chronic methotrexate (MTX)...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related